NCT02187783: A reported trial by Novartis Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02187783 |
|---|---|
| Title | Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 25, 2014 |
| Completion date | Jan. 17, 2018 |
| Required reporting date | Jan. 17, 2019, midnight |
| Actual reporting date | Jan. 16, 2019 |
| Date last checked at ClinicalTrials.gov | May 26, 2025 |
| Days late | None |